Creative Biolabs engineers CXCR3-matched CAR-T cells to leverage CXCL9/10/11 gradients in solid tumors, enhancing directional trafficking, deep infiltration, and improved antitumor activity within inflamed tumor microenvironments.
Creative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
EXPLORE MORE HighlightsWe focus on unmet needs and develop novel cellular and gene drugs and solutions that offer significant benefits over existing options.
EXPLORE MORE HighlightsThe advent of Chimeric Antigen Receptor T-cell (CAR-T) therapies has revolutionized the field of oncology, providing new avenues for treating various forms of cancer. Our 20 years of experience in the biotechnology sector have equipped us with the expertise and technological capabilities to support the entire lifecycle of CAR-T products, from early development to commercialization.
EXPLORE MORETo accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
EXPLORE MORE HighlightsUse the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don't find the answers you're looking for, contact us for additional assistance.
EXPLORE MORE HighlightsGet a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
EXPLORE MORE
Creative Biolabs provides a CCL19/9–CCR7 Chemokine-Axis Matching CAR-T Development Service for Solid Tumor Targeting, designed to overcome insufficient T-cell infiltration and limited CAR-T persistence. Through precise chemokine receptor engineering and tumor microenvironment (TME)-informed co-expression strategies, our platform enhances directed trafficking, tumor homing, and sustained antitumor activity.
CAR T cell therapy has limited efficacy against solid tumors due to the hostile TME, leading to immune exclusion and T cell exhaustion. The CCL19/9-CCR7 Chemokine Axis Matching strategy is a validated, fourth-generation approach that programs T cells to secrete chemokines, such as CCL19. This secretion significantly enhances CAR-T cell migration and infiltration into the tumor mass.
Our service provides the advanced engineering solution required to transition your CAR-T pipeline from hematological success to solid tumor efficacy. We focus on enhancing the intrinsic motility and survival signaling of your therapeutic T cells.
Discover How We Can Help - Request a Consultation.
Creative Biolabs utilizes high-end molecular engineering and comprehensive functional screening platforms to implement the CCL19/9-CCR7 Chemokine Axis strategy. Our platform offerings ensure optimal CAR-T design, manufacturing, and preclinical validation.
The required starting materials include target antigen details, the source of T cells (for example, PBMCs or leukapheresis material), as well as the target indication and tumor model requirements.
This study aims to enhance CAR-T cell therapy for solid tumors, which typically respond poorly. Researchers engineered human CAR-T cells to secrete the proteins IL-7 and CCL19, which improved the cells' expansion and ability to migrate into tumors. These modified cells demonstrated significantly superior tumor suppression, leading to complete or near-complete tumor regression in patients with advanced liver and pancreatic cancer.
Fig.1 Construction and flow cytometry analysis of CAR-T cells.1
Why use CCL19/9-CCR7 matching instead of increasing the CAR-T dose?
Dose escalation cannot overcome immune exclusion. Our approach actively guides T-cells into the tumor via chemokine gradients and extends local survival, achieving what higher doses cannot.
How do you ensure safety after chemokine engineering?
Rigorous QC (flow cytometry, cytotoxicity assays) confirms maintained memory phenotypes with no off-target activation or unsafe proliferation.
Can this be combined with other TME-targeting strategies?
Yes. The CCL19/9-CCR7 axis can be co-expressed with dominant-negative TGF-β Receptor to simultaneously enhance homing and block immunosuppressive signals.
Which tumors is this strategy best for?
Ideal for stroma-rich, T-cell-excluded tumors like HCC, pancreatic, and ovarian cancers. The approach is target-agnostic and enhances any TAA-directed CAR.
Creative Biolabs engineers CXCR3-matched CAR-T cells to leverage CXCL9/10/11 gradients in solid tumors, enhancing directional trafficking, deep infiltration, and improved antitumor activity within inflamed tumor microenvironments.
Creative Biolabs develops CXCR6-equipped CAR-T cells that exploit CXCL16-rich tumor niches, promoting efficient homing, retention, and sustained cytotoxicity in dense or poorly accessible solid tumors.
Creative Biolabs creates CXCR1/2-matched CAR-T cells to respond to CXCL1/8 chemokine signals, significantly improving migration toward immunosuppressive solid tumors and enhancing overall therapeutic potency.
The CCL19/9-CCR7 Chemokine-Axis Matching CAR-T Development Service from Creative Biolabs represents the next critical step in cancer immunotherapy. By moving beyond simple targeting to active TME remodeling and directed cellular homing, we provide the solution for enhanced efficacy, superior persistence, and a highly competitive safety profile. Trust our two decades of expertise to transform your CAR-T candidate into a potent, durable force against the most challenging solid tumors. Ready to discuss how our Armored CAR-T platform can de-risk your pipeline and deliver groundbreaking clinical results? Contact our team to get a custom proposal.
Reference
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION